ID   MSTO-211H
AC   CVCL_1430
SY   MSTO-211 H; MSTO211H; MSTO-211; 211H; MeSoTheliOma-211H
DR   BTO; BTO_0002425
DR   CLO; CLO_0007880
DR   EFO; EFO_0002839
DR   CLDB; cl7174
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2081
DR   BioSample; SAMN03471440
DR   BioSample; SAMN10987652
DR   BioSamples; SAMEA100779
DR   cancercelllines; CVCL_1430
DR   CCRID; 3101HUMTCHu161
DR   Cell_Model_Passport; SIDM00640
DR   ChEMBL-Cells; CHEMBL3308116
DR   ChEMBL-Targets; CHEMBL1075509
DR   CLS; 300450
DR   Cosmic; 688057
DR   Cosmic; 877275
DR   Cosmic; 908152
DR   Cosmic; 1067228
DR   Cosmic; 1175876
DR   Cosmic; 1481542
DR   Cosmic; 1522772
DR   Cosmic; 1541211
DR   Cosmic; 1749563
DR   Cosmic; 1963324
DR   Cosmic; 1995515
DR   Cosmic; 2759001
DR   Cosmic; 2759223
DR   Cosmic-CLP; 908152
DR   DepMap; ACH-000335
DR   DSMZ; ACC-390
DR   DSMZCellDive; ACC-390
DR   EGA; EGAS00001000978
DR   GDSC; 908152
DR   GEO; GSM49614
DR   GEO; GSM726279
DR   GEO; GSM827586
DR   GEO; GSM850286
DR   GEO; GSM887342
DR   GEO; GSM888418
DR   GEO; GSM1670136
DR   IARC_TP53; 21518
DR   ICLC; HL01018
DR   LiGeA; CCLE_249
DR   LINCS_LDP; LCL-1776
DR   PharmacoDB; MSTO211H_968_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1430
DR   PubChem_Cell_line; CVCL_1430
DR   Ubigene; YC-B014
DR   Wikidata; Q54906900
RX   PubMed=2840315;
RX   PubMed=15920167;
RX   PubMed=16630136;
RX   PubMed=17270034;
RX   PubMed=20215515;
RX   PubMed=21245096;
RX   PubMed=21642991;
RX   PubMed=22460905;
RX   PubMed=24926545;
RX   PubMed=25902174;
RX   PubMed=26011428;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28553954;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   Provider; Altogen; Xenograft model; https://altogenlabs.com/xenograft-models/other-bladder-cervical/msto-211h-xenograft-model/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MYC genetic alteration cell panel (ATCC TCP-1035).
CC   Population: Caucasian.
CC   Doubling time: 20 hours (PubMed=2840315); 20 hours (CLS=300450); ~30-40 hours (DSMZ=ACC-390).
CC   HLA typing: A*01:01,03:01; B*07:02,39:01; C*07:02,07:02; DRB1*01:02,01:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136).
CC   Sequence variation: Gene fusion; HGNC; HGNC:6514; LATS1 + HGNC; HGNC:9508; PSEN1; Name(s)=LATS1-PSEN1 (PubMed=25902174).
CC   Sequence variation: Mutation; HGNC; HGNC:6515; LATS2; Simple; p.Met785_Leu798del14 (c.2355_2396del42); Zygosity=Heterozygous (PubMed=21245096; Cosmic-CLP=908152; DepMap=ACH-000335).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; Array-based CGH.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=0%; Native American=0.17%; East Asian, North=1.28%; East Asian, South=0%; South Asian=2.13%; European, North=62.92%; European, South=33.49% (PubMed=30894373).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC=CRL-2081; CLS=300450; Cosmic-CLP=908152; DSMZ=ACC-390; Technion Genomics Center
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,14
ST   D16S539: 13
ST   D18S51: 16,18 (ATCC=CRL-2081; CLS=300450; DSMZ=ACC-390)
ST   D18S51: 18,19 (Technion Genomics Center)
ST   D19S433: 13,14
ST   D21S11: 28,31
ST   D2S1338: 20,24
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 8,12
ST   D8S1179: 13
ST   FGA: 21
ST   Penta D: 11,12
ST   Penta E: 7,13
ST   TH01: 8,9.3
ST   TPOX: 11
ST   vWA: 16,18
DI   NCIt; C45665; Pleural biphasic mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 42
//
RX   PubMed=2840315; DOI=10.1111/j.1432-0436.1988.tb00806.x;
RA   Bepler G., Koehler A., Kiefer P., Havemann K., Beisenherz K.,
RA   Jaques G., Gropp C., Haeder M.;
RT   "Characterization of the state of differentiation of six newly
RT   established human non-small-cell lung cancer cell lines.";
RL   Differentiation 37:158-171(1988).
//
RX   PubMed=15920167; DOI=10.1016/S0002-9440(10)62492-3; PMCID=PMC1363736;
RA   Gordon G.J., Rockwell G.N., Jensen R.V., Rheinwald J.G.,
RA   Glickman J.N., Aronson J.P., Pottorf B.J., Nitz M.D., Richards W.G.,
RA   Sugarbaker D.J., Bueno R.;
RT   "Identification of novel candidate oncogenes and tumor suppressors in
RT   malignant pleural mesothelioma using large-scale transcriptional
RT   profiling.";
RL   Am. J. Pathol. 166:1827-1840(2005).
//
RX   PubMed=16630136; DOI=10.1111/j.1349-7006.2006.00184.x; PMCID=PMC11158456;
RA   Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S.,
RA   Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.;
RT   "Establishment and characterization of four malignant pleural
RT   mesothelioma cell lines from Japanese patients.";
RL   Cancer Sci. 97:387-394(2006).
//
RX   PubMed=17270034; DOI=10.1111/j.1349-7006.2006.00386.x; PMCID=PMC11158069;
RA   Taniguchi T., Karnan S., Fukui T., Yokoyama T., Tagawa H., Yokoi K.,
RA   Ueda Y., Mitsudomi T., Horio Y., Hida T., Yatabe Y., Seto M.,
RA   Sekido Y.;
RT   "Genomic profiling of malignant pleural mesothelioma with array-based
RT   comparative genomic hybridization shows frequent non-random
RT   chromosomal alteration regions including JUN amplification on 1p32.";
RL   Cancer Sci. 98:438-446(2007).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164;
RA   Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T.,
RA   Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H.,
RA   Sekido Y.;
RT   "LATS2 is a tumor suppressor gene of malignant mesothelioma.";
RL   Cancer Res. 71:873-883(2011).
//
RX   PubMed=21642991; DOI=10.1038/ng.855; PMCID=PMC4643098;
RA   Bott M.J., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L.,
RA   Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R.,
RA   Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.;
RT   "The nuclear deubiquitinase BAP1 is commonly inactivated by somatic
RT   mutations and 3p21.1 losses in malignant pleural mesothelioma.";
RL   Nat. Genet. 43:668-672(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24926545; DOI=10.1097/JTO.0000000000000202; PMCID=PMC4287384;
RA   Riquelme E., Suraokar M.B., Rodriguez J., Mino B., Lin H.Y.,
RA   Rice D.C., Tsao A., Wistuba I.I.;
RT   "Frequent coamplification and cooperation between C-MYC and PVT1
RT   oncogenes promote malignant pleural mesothelioma.";
RL   J. Thorac. Oncol. 9:998-1007(2014).
//
RX   PubMed=25902174; DOI=10.1097/JTO.0000000000000493;
RA   Miyanaga A., Masuda M., Tsuta K., Kawasaki K., Nakamura Y., Sakuma T.,
RA   Asamura H., Gemma A., Yamada T.;
RT   "Hippo pathway gene mutations in malignant mesothelioma: revealed by
RT   RNA and targeted exon sequencing.";
RL   J. Thorac. Oncol. 10:844-851(2015).
//
RX   PubMed=26011428; DOI=10.1111/cas.12698; PMCID=PMC4556387;
RA   Hakiri S., Osada H., Ishiguro F., Murakami H., Murakami-Tonami Y.,
RA   Yokoi K., Sekido Y.;
RT   "Functional differences between wild-type and mutant-type
RT   BRCA1-associated protein 1 tumor suppressor against malignant
RT   mesothelioma cells.";
RL   Cancer Sci. 106:990-999(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28553954; DOI=10.1038/onc.2017.147;
RA   Kato T., Sato T., Yokoi K., Sekido Y.;
RT   "E-cadherin expression is correlated with focal adhesion kinase
RT   inhibitor resistance in merlin-negative malignant mesothelioma
RT   cells.";
RL   Oncogene 36:5522-5531(2017).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:e0210404.1-e0210404.22(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//